Terry Flotte, outgoing president of ASGCT, highlights initiatives aimed at improving access to rare disease cell and gene therapies. Key among these is the launch of CGTxchange, an AI-enabled platform designed to facilitate the continuation of promising but financially unviable clinical-stage treatments. This effort underscores the growing importance of innovative solutions for advancing rare disease research and therapy development.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





